Impact of a Stage IV NSCLC care pathway on front-line (FL) and maintenance (M) chemotherapy use at the Cleveland Clinic Taussig Cancer Institute (TCI).

Shapiro, Marc A.; Stevenson, James P.; Wagoner, Emily Van; Glass, Katherine; Cummings, Chad W.; Pennell, Nathan A.; Patrick, C.; Velcheti, Vamsidhar; Bastos, Bruno R.; Bolwell, Brian J.; Haddad, Abdo

doi:10.1200/jco.2015.33.15_suppl.6609

Search citation statements

Order By: Relevance

Paper Sections

Select...

Discussion1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2016

2017

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the implementation of a clinical pathway in NSCLC, we have documented a significant cost savings after pathway implementation with no adverse effects on clinical outcomes. Our findings echo those reported by Shapiro et al, 8 with our data demonstrating the cost savings over a larger cohort encompassing a broader population (all patients with stage IV NSCLC, not just patients with nonsquamous disease).…”

Section: Discussionsupporting

confidence: 91%